GlassScriptPhysician profile
Phaedra Hockman
NPI 1659008548
$4,089.55
in general payments reported to CMS, 2019-2025
25 companies · $2,589 in 2025
The $2,589 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.04 · 2023: $457 · 2024: $988 · 2025: $2,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,844.21 |
| Education | $189.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,099.01 | 2023-2025 | |
| Janssen Biotech, INC. | $487.11 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $357.55 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $246.93 | 2025 | Nemluvio, Aklief |
| Ucb, INC. | $242.87 | 2024-2025 | Bimzelx |
| Organon LLC | $201.89 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $192.52 | 2022-2024 | Ilumya |
| Novartis Pharmaceuticals Corporation | $185.88 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $162.76 | 2024-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $137.85 | 2023-2024 | Vtama |
| Genzyme Corporation | $108.06 | 2023-2025 | |
| Incyte Corporation | $94.37 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $92.18 | 2024-2025 | Adbry |
| Amgen INC. | $80.20 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $64.66 | 2023-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $54.41 | 2023-2024 | Ycanth |
| Almirall LLC | $53.04 | 2025 | Klisyri, Cordran, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.06 | 2025 | Cabtreo |
| Botanix Sb INC | $37.71 | 2025 | Sofdra |
| Lilly USA, LLC | $31.73 | 2025 | Ebglyss |
| Kyowa Kirin, INC. | $28.93 | 2025 | |
| Alnylam Pharmaceuticals INC. | $27.64 | 2024 | Givlaari |
| Journey Medical Corporation | $23.38 | 2025 | |
| Pfizer INC. | $19.14 | 2024 | |
| Integra Lifesciences Corporation | $17.67 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phaedra Hockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.